Medicare Enrolled
Dr. Reza Nazemi, M.D.
Endocrinology · Beverly Hills, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nazemi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nazemi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nazemi
Dr. Reza Nazemi is an endocrinology specialist in Beverly Hills, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Nazemi performed 11,624 Medicare services across 5,224 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nazemi received a total of $108,342 from 80 pharmaceutical and/or device companies across 1666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nazemi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 7% volume in CA
$108,342 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,624
Medicare services
Top 7% in CA for endocrinology
5,224
Unique beneficiaries
$70
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~612 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,544 | $111 | $306 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
2,344 | $68 | $270 |
| Hemoglobin a1c level, by device for home use | 1,283 | $10 | $33 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,283 | $102 | $334 |
| Blood glucose test using hand-held instrument A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels. |
1,134 | $3 | $25 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
825 | $8 | $30 |
| Ultrasound of head and neck soft tissue This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation. |
404 | $105 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
402 | $152 | $463 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
383 | $30 | $175 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
272 | $111 | $411 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
183 | $142 | $510 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
177 | $146 | $530 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
145 | $12 | $57 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
69 | $1 | $20 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
52 | $79 | $232 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
43 | $51 | $222 |
| Ultrasound-guided fine needle aspiration biopsy, first lesion A biopsy procedure where a thin needle is used to collect tissue samples from a growth, guided by ultrasound imaging. This code applies to the first lesion or mass sampled during the session. |
31 | $123 | $616 |
| Continuous glucose monitoring, sensor under skin This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin with provider-supplied equipment. |
20 | $138 | $250 |
| New patient office visit, complex (60-74 min) | 16 | $193 | $578 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
14 | $71 | $375 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$108,342
Total received (2018-2024)
Avg $15,477/year across 7 years
Top 5% in CA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
80
Companies
1,666
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$77,364 (71.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,358 (21.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,620 (7.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$12,319
2023
$9,522
2022
$11,172
2021
$14,117
2020
$12,164
2019
$23,973
2018
$25,075
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$4,932
Lilly USA, LLC
$3,369
Novo Nordisk Inc
$376
Corcept Therapeutics
$365
Abbott Laboratories
$352
Mannkind Corporation
$302
Amgen Inc.
$263
Radius Health, Inc.
$259
ABBVIE INC.
$227
Xeris Pharmaceuticals, Inc.
$225
Dexcom, Inc.
$196
RECORDATI_RARE_DISEASES_INC.
$192
Insulet Corporation
$189
Ascensia Diabetes Care Us Inc.
$137
IBSA Pharma Inc.
$112
Tandem Diabetes Care, Inc.
$105
Novartis Pharmaceuticals Corporation
$90
Medtronic, Inc.
$77
CeQur Corporation
$69
Lexicon Pharmaceuticals, Inc.
$53
Alexion Pharmaceuticals, Inc.
$51
Alvogen Inc
$44
Astellas Pharma US Inc
$42
Bayer Healthcare Pharmaceuticals Inc.
$42
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$38
Regeneron Healthcare Solutions, Inc.
$36
SANOFI-AVENTIS U.S. LLC
$32
Currax Pharmaceuticals LLC
$31
Acella Pharmaceuticals, LLC
$30
BETA BIONICS, INC.
$27
Antares Pharma, Inc.
$22
Tolmar, Inc.
$19
Intra-Sana Laboratories
$18
Top 3 companies account for 70.4% of 2024 payments
All-time payments by company (2018-2024) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$33,105
AstraZeneca Pharmaceuticals LP
$32,837
Lilly USA, LLC
$16,488
Corcept Therapeutics
$3,651
Novo Nordisk Inc
$3,368
Amgen Inc.
$1,546
Insulet Corporation
$1,434
SANOFI-AVENTIS U.S. LLC
$1,412
Radius Health, Inc.
$1,123
Abbott Laboratories
$1,107
IBSA Pharma Inc.
$882
ABBVIE INC.
$739
Mannkind Corporation
$700
Janssen Pharmaceuticals, Inc
$668
Merck Sharp & Dohme Corporation
$638
MannKind Corporation
$574
AbbVie Inc.
$516
Currax Pharmaceuticals LLC
$454
AbbVie, Inc.
$421
RECORDATI_RARE_DISEASES_INC.
$389
Bayer HealthCare Pharmaceuticals Inc.
$384
Tandem Diabetes Care, Inc.
$374
Dexcom, Inc.
$357
Xeris Pharmaceuticals, Inc.
$352
Becton, Dickinson and Company
$301
Alexion Pharmaceuticals, Inc.
$282
Novartis Pharmaceuticals Corporation
$277
Amarin Pharma Inc.
$237
Medtronic, Inc.
$210
Bayer Healthcare Pharmaceuticals Inc.
$193
Horizon Therapeutics plc
$189
Endo Pharmaceuticals Inc.
$181
Shire North American Group Inc
$170
Embecta Corp.
$163
Watermark Medical, Inc.
$146
Ascensia Diabetes Care Us Inc.
$137
Eisai Inc.
$131
Valeritas, Inc.
$117
Zealand Pharma US, Inc.
$116
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$113
CeQur Corporation
$113
Gemini Laboratories, LLC
$111
LifeScan, Inc.
$100
Alvogen Inc
$99
Antares Pharma, Inc.
$93
Alfasigma USA, Inc.
$85
EUSA Pharma (US) LLC
$84
Regeneron Healthcare Solutions, Inc.
$78
Lexicon Pharmaceuticals, Inc.
$74
Ipsen Biopharmaceuticals, Inc
$73
Medtronic MiniMed, Inc.
$64
GRT US Holding, Inc.
$61
VIVUS, Inc.
$59
Kyowa Kirin, Inc.
$56
ARBOR PHARMACEUTICALS, INC.
$49
Supernus Pharmaceuticals, Inc.
$48
Kowa Pharmaceuticals America, Inc.
$47
Astellas Pharma US Inc
$42
Clarus Therapeutics Inc.
$41
Amneal Pharmaceuticals LLC
$36
Tolmar, Inc.
$33
Acella Pharmaceuticals, LLC
$30
BETA BIONICS, INC.
$27
Biohaven Pharmaceutical Holding Company Ltd.
$27
Senseonics, Incorporated
$27
Bigfoot Biomedical Inc
$26
LIFESCAN, INC.
$25
Exact Sciences Corporation
$24
VIVUS LLC
$23
Amryt Pharma Holdings Ltd
$23
Esperion Therapeutics, Inc.
$21
DEXCOM, INC.
$20
Biohaven Pharmaceuticals, Inc.
$19
Nalpropion Pharmaceuticals LLC
$19
Acerus Pharmaceuticals Corporation
$19
ASCEND Therapeutics US, LLC
$18
Arbor Pharmaceuticals, Inc.
$18
Intra-Sana Laboratories
$18
EISAI INC.
$18
Optos, Inc.
$15
Top 3 companies account for 76.1% of all-time payments
Associated products mentioned in payments ›
ACCURIAN · AFREZZA · ARES HOME SLEEP TESTING DEVICE · Aimovig · Androgel · BAQSIMI · BASAGLAR · BD Nano · BD Nano 2nd Gen Pen Needle · BD Ultra-Fine · BELSOMRA · BINOSTO · BYDUREON · Belviq · CONTRAVE · CeQur Simplicity · Cologuard Collection Kit · Creon · Crysvita · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · Dayvigo · Dexcom CGM · Dexcom G6 Transmitter · EVENITY · EVERSENSE 365 SENSOR KIT (RETAIL) · EVERSENSE E3 SENSOR KIT - RETAIL · EVKEEZA · Edarbi · Eversense · FARXIGA · FORTEO · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · Guardian Connect · HUMALOG · HUMULIN · INVOKANA · ISTURISA · Inpefa · JANUVIA · JARDIANCE · JATENZO · Kerendia · Korlym · LEQVIO · LICART · LINZESS · Licart · Livalo · MINIMED 780G · MOUNJARO · MYCAPSSA · Minimed 670G System · Minimed 770G System · NASCOBAL · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NOCDURNA · NP Thyroid 60 · NURTEC ODT · Natesto · ONETOUCH VERIO REFLECT · OT Verio Reflect "One Touch Meter and Strips" · Omnipod · OneTouch · OneTouch Verio Reflect · Ozempic · PANORAMIC OPHTHALMOSCOPE · PRALUENT · Prolia · QSYMIA · QULIPTA · Qutenza · RECORLEV · RELTONE 200 MG · RETEVMO · RYBELSUS · Repatha · Rybelsus · SIGNIFOR LAR · SOLIQUA · SOLIQUA 100/33 · SOMATULINE DEPOT · STEGLATRO · STRENSIQ · SYNJARDY · SYNTHROID · Saxenda · Strensiq · Sylvant · Synthroid · TEPEZZA · TERIPARATIDE · TLANDO · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Tirosint · Tresiba · Tymlos · UBRELVY · UNITHROID · UNITY DIABETES MANAGEMENT SYSTEM · V-GO · V-GO DISPOSABLE INSULIN DELIVERY · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XIFAXAN · ZEGALOGUE · ZEPBOUND · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (71%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for endocrinology in CA.
Geographic Context
Endocrinologists within 10 mi
261
Per 100K population
2.7
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
1.8 mi
1.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nazemi is a clinical cardiology specialist, with above-average Medicare volume (top 7% in CA), with speaking/promotional industry engagement in the top 5% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nazemi experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Nazemi performed 2,544 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nazemi receive payments from pharmaceutical companies?
Yes. Dr. Nazemi received a total of $108,342 from 80 companies across 1,666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nazemi's costs compare to other endocrinologists in Beverly Hills?
Dr. Nazemi's average Medicare payment per service is $70. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nazemi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in Beverly Hills
Browse endocrinologists in Beverly Hills ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in CA
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in CA
Which CA endocrinologists receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology